Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT01062152 is registered in ClinicalTrials.gov with Telik as lead sponsor.

NCT NCT01062152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01062152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Lead sponsor
Telik
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2009
Completion date
March 31, 2013
Enrollment
19 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome